The etiologies of primary and acquired resistance to immunotherapy are multifaceted, and include the interplay between cancer and its TME, tumor immunogenicity (dependent on the tumor mutation profile, the tumor mutation burden and the patient's MHC variants), tumor heterogeneity, and patient's underlying immune status. The gene discussed is HLA-C; the disease is neoplasm.